Literature DB >> 21756082

Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers.

Charles A Kunos1, Gina Ferris, Natalie Pyatka, John Pink, Tomas Radivoyevitch.   

Abstract

Cells generate 2'-deoxyribonucleoside triphosphates (dNTPs) for both replication and repair of damaged DNA predominantly through de novo reduction of intracellular ribonucleotides by ribonucleotide reductase (RNR). Cells can also salvage deoxynucleosides by deoxycytidine kinase/thymidine kinase 1 in the cytosol or by deoxyguanosine kinase/thymidine kinase 2 in mitochondria. In this study we investigated whether the salvage dNTP supply pathway facilitates DNA damage repair, promoting cell survival, when pharmacological inhibition of RNR by 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC no. 663249) impairs the de novo pathway. Human cervical cancer cells were subjected to radiation with or without 3-AP under medium deoxynucleoside concentrations of 0, 0.05, 0.5 and 5.0 µM. Efficacy of DNA damage repair was assessed by γ-H2AX flow cytometry and focus counts, by single cell electrophoresis (Comet assay), and by caspase 3 cleavage assay as a marker of treatment-induced apoptosis. Cell survival was assessed by colony formation. We found that deoxyribonucleotide salvage facilitates DNA repair during RNR inhibition by 3-AP and that salvage reduces the radiochemosensitivity of human cervical cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756082      PMCID: PMC3191339          DOI: 10.1667/rr2556.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  27 in total

1.  Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase.

Authors:  Hiroyuki Niida; Yuko Katsuno; Misuzu Sengoku; Midori Shimada; Megumi Yukawa; Masae Ikura; Tsuyoshi Ikura; Kazuteru Kohno; Hiroki Shima; Hidekazu Suzuki; Satoshi Tashiro; Makoto Nakanishi
Journal:  Genes Dev       Date:  2010-02-15       Impact factor: 11.361

2.  Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks.

Authors:  A Chabes; L Thelander
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

3.  Clinical value of thymidine kinase in patients with cervical carcinoma.

Authors:  R Fujiwaki; K Hata; M Moriyama; O Iwanari; H Katabuchi; H Okamura; K Miyazaki
Journal:  Oncology       Date:  2001       Impact factor: 2.935

4.  Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.

Authors:  Charles A Kunos; Steven Waggoner; Vivian von Gruenigen; Elisa Eldermire; John Pink; Afshin Dowlati; Timothy J Kinsella
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 5.  Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib).

Authors:  M W Ritzel; A M Ng; S Y Yao; K Graham; S K Loewen; K M Smith; R J Hyde; E Karpinski; C E Cass; S A Baldwin; J D Young
Journal:  Mol Membr Biol       Date:  2001 Jan-Mar       Impact factor: 2.857

6.  Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; John Pink; Song-Mao Chiu; Tammy Stefan; James Jacobberger; Timothy J Kinsella
Journal:  Radiat Res       Date:  2010-09-10       Impact factor: 2.841

Review 7.  Radiologic measurements of tumor response to treatment: practical approaches and limitations.

Authors:  Chikako Suzuki; Hans Jacobsson; Thomas Hatschek; Michael R Torkzad; Katarina Bodén; Yvonne Eriksson-Alm; Elisabeth Berg; Hirofumi Fujii; Atsushi Kubo; Lennart Blomqvist
Journal:  Radiographics       Date:  2008 Mar-Apr       Impact factor: 5.333

8.  Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.

Authors:  Charles A Kunos; Song-mao Chiu; John Pink; Timothy J Kinsella
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

Review 9.  Nucleoside transporter proteins.

Authors:  Míriam Molina-Arcas; F Javier Casado; Marçal Pastor-Anglada
Journal:  Curr Vasc Pharmacol       Date:  2009-10       Impact factor: 2.719

10.  Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure.

Authors:  Eric L Chang; Almon S Shiu; Ehud Mendel; Leni A Mathews; Anita Mahajan; Pamela K Allen; Jeffrey S Weinberg; Barry W Brown; Xin Shelly Wang; Shiao Y Woo; Charles Cleeland; Moshe H Maor; Laurence D Rhines
Journal:  J Neurosurg Spine       Date:  2007-08
View more
  18 in total

1.  Molecular Strategies of Deoxynucleotide Triphosphate Supply Inhibition Used in the Treatment of Gynecologic Malignancies.

Authors:  Charles A Kunos; Tomas Radivoyevitch
Journal:  Gynecol Obstet (Sunnyvale)       Date:  2011-12-10

2.  Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; Adam Kresak; Dawn Dawson; James Jacobberger; Bin Yang; Fadi W Abdul-Karim
Journal:  Int J Gynecol Cancer       Date:  2012-11       Impact factor: 3.437

3.  Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.

Authors:  Charles A Kunos; Edward Chu; Jan H Beumer; Mario Sznol; S Percy Ivy
Journal:  Cancer Chemother Pharmacol       Date:  2016-11-22       Impact factor: 3.333

Review 4.  Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.

Authors:  Charles A Kunos; Tomas Radivoyevitch; Stephen T Ingalls; Charles L Hoppel
Journal:  Future Oncol       Date:  2012-02       Impact factor: 3.404

5.  A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.

Authors:  R R Naik; A K Singh; A M Mali; M F Khirade; S A Bapat
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

6.  Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; Steven Waggoner; Robert Debernardo; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Raymond Redline; Peter Faulhaber; Afshin Dowlati
Journal:  Gynecol Oncol       Date:  2013-04-18       Impact factor: 5.482

7.  Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.

Authors:  Charles A Kunos; Kathryn Winter; Adam P Dicker; William Small; Fadi W Abdul-Karim; Dawn Dawson; Anuja Jhingran; Richard Valicenti; Joanne B Weidhaas; David K Gaffney
Journal:  Int J Gynecol Cancer       Date:  2013-05       Impact factor: 3.437

8.  Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer.

Authors:  Charles A Kunos
Journal:  Oncol Hematol Rev       Date:  2012

9.  Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  Charles Kunos; Tomas Radivoyevitch; Fadi W Abdul-Karim; James Fanning; Ovadia Abulafia; Albert J Bonebrake; Lydia Usha
Journal:  J Transl Med       Date:  2012-04-27       Impact factor: 5.531

10.  Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.

Authors:  Lauren Shunkwiler; Gina Ferris; Charles Kunos
Journal:  Int J Mol Sci       Date:  2013-02-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.